Author

M. Feigin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1

Frequent Co-Authors

B. S. Katzenellenbogen· 1 shared C. A. Natale· 1 shared I. Y. Lee· 1 shared J. A. Katzenellenbogen· 1 shared M. Doepner· 1 shared S. H. Kim· 1 shared S. Venkat· 1 shared T. W. Ridky· 1 shared

Activity by Year

2021-2021 · peak 1/yr

Co-Author Collaboration Network

8 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

B. S. Katzenellenbogen

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

CHRM1 is a Druggable Melanoma Target Whose Endogenous Activity is Determined by Inherited Genetic Variation in DOPA Production

M. Doepner, C. A. Natale, I. Y. Lee, S. Venkat, S. H. Kim, J. A. Katzenellenbogen, B. S. Katzenellenbogen, M. Feigin, T. W. Ridky

This study identifies CHRM1 as a druggable melanoma target influenced by genetic variation in DOPA production, showing DOPA inhibits CHRM1 to suppress melanoma proliferation.

bioRxiv · Mar 3, 2021 · PreprintCancer Biology